Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $10.98 USD
Change Today -0.15 / -1.35%
Volume 105.6K
DRNA On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 3:48 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Douglas M. Fambrough III, Ph.D.

Co-Founder, Chief Executive Officer, President and Director,Dicerna Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 18 board members in 2 different organizations across 6 different industries.

See Board Relationships
46$5,288,443
As of Fiscal Year 2014

Background*

Dr. Douglas M. Fambrough, III, Ph.D., is the Co-Founder Dicerna Pharmaceuticals, Inc. and has been its Chief Executive Officer and President since May 2010. Dr. Fambrough served as a Venture Partner at Oxford Bioscience Partners and focused his investments on innovative life science technology companies. Dr. Fambrough joined the Oxford Bioscience Partners in 1999 as an Associate and became a Principal in 2001. He became a Partner in 2005 and served as its General Partner ...

Read Full Background

Corporate Headquarters*

87 Cambridgepark Drive
Cambridge, Massachusetts 02140

United States

Phone: 617-621-8097
Fax: 617-612-6298

Board Members Memberships*

Observer
2007-Present
Co-Founder, Chief Executive Officer, President and Director

Education*

Bachelor's Degree
Cornell University
Master's Degree
Cornell University
PhD
University of California Berkeley

Other Affiliations*

Annual Compensation*

Salary$430,000
Total Annual Compensation$430,000

Stock Options*

All Other Compensation$10,490
Exercisable Options392,192
Unexercisable Options529,708
Total Number of Options1,034,400

Total Compensation*

Total Annual Cash Compensation$633,754
Total Short Term Compensation$430,000
Other Long Term Compensation$10,490
Total Calculated Compensation$5,288,443
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DRNA:US $10.98 USD -0.15

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ali Mortazavi Chief Executive (leave of absence) and Director
Silence Therapeutics plc
200.0K GBP
J. Michael French Chairman, Chief Executive Officer and President
Marina Biotech, Inc.
$288.1K
Peter French B.Sc, M.Sc, Ph.D., MBAChief Executive Officer, Managing Director and Director
Benitec Biopharma Limited
A$450.0K
Mark W. Schwartz Ph.D.Chief Executive Officer, President, Director and Member of Ad Hoc (Strategy, Pricing, Etc) Committee
Galena Biopharma, Inc.
$707.1K
Mark Joseph Murray Ph.D.Chief Executive Officer, President and Director
Arbutus Biopharma Corporation
$580.0K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DICERNA PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.